Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas.

Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ.

Leukemia. 2008 May;22(5):1026-34. doi: 10.1038/leu.2008.9. Epub 2008 Feb 7.

PMID:
18256683
2.

Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.

Suzuki T, Ota Y, Ri M, Bando M, Gotoh A, Itoh Y, Tsumoto H, Tatum PR, Mizukami T, Nakagawa H, Iida S, Ueda R, Shirahige K, Miyata N.

J Med Chem. 2012 Nov 26;55(22):9562-75. doi: 10.1021/jm300837y. Epub 2012 Nov 12.

PMID:
23116147
3.

HDAC8-mediated epigenetic reprogramming plays a key role in resistance to anthrax lethal toxin-induced pyroptosis in macrophages.

Ha SD, Han CY, Reid C, Kim SO.

J Immunol. 2014 Aug 1;193(3):1333-43. doi: 10.4049/jimmunol.1400420. Epub 2014 Jun 27.

4.

Apicidin induces endoplasmic reticulum stress- and mitochondrial dysfunction-associated apoptosis via phospholipase Cγ1- and Ca(2+)-dependent pathway in mouse Neuro-2a neuroblastoma cells.

Choi JH, Lee JY, Choi AY, Hwang KY, Choe W, Yoon KS, Ha J, Yeo EJ, Kang I.

Apoptosis. 2012 Dec;17(12):1340-58. doi: 10.1007/s10495-012-0755-9.

PMID:
22926926
5.

Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.

Suzuki T, Muto N, Bando M, Itoh Y, Masaki A, Ri M, Ota Y, Nakagawa H, Iida S, Shirahige K, Miyata N.

ChemMedChem. 2014 Mar;9(3):657-64. doi: 10.1002/cmdc.201300414. Epub 2014 Jan 8.

PMID:
24403121
6.

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.

Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF, Gillespie J, Wang JJ, Ste-Croix H, Rahil J, Lefebvre S, Moradei O, Delorme D, Macleod AR, Besterman JM, Li Z.

Mol Cancer Ther. 2008 Apr;7(4):759-68. doi: 10.1158/1535-7163.MCT-07-2026.

7.

PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.

Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, Gordon LI, Evens AM.

Clin Cancer Res. 2009 May 15;15(10):3354-65. doi: 10.1158/1078-0432.CCR-08-2365. Epub 2009 May 5. Erratum in: Clin Cancer Res. 2009 Jul 15;15(14):4784-5.

8.
9.

Potent and Selective Non-hydroxamate Histone Deacetylase 8 Inhibitors.

Kleinschek A, Meyners C, Digiorgio E, Brancolini C, Meyer-Almes FJ.

ChemMedChem. 2016 Dec 6;11(23):2598-2606. doi: 10.1002/cmdc.201600528. Epub 2016 Nov 9.

PMID:
27860422
10.

HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST).

Lopez G, Bill KL, Bid HK, Braggio D, Constantino D, Prudner B, Zewdu A, Batte K, Lev D, Pollock RE.

PLoS One. 2015 Jul 22;10(7):e0133302. doi: 10.1371/journal.pone.0133302. eCollection 2015.

11.

CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo.

Cao ZA, Bass KE, Balasubramanian S, Liu L, Schultz B, Verner E, Dai Y, Molina RA, Davis JR, Misialek S, Sendzik M, Orr CJ, Leung L, Callan O, Young P, Dalrymple SA, Buggy JJ.

Mol Cancer Ther. 2006 Jul;5(7):1693-701.

12.

The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.

Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ, Zhao WL.

Leukemia. 2009 Aug;23(8):1507-14. doi: 10.1038/leu.2009.41. Epub 2009 Mar 12.

PMID:
19282831
13.

Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells.

Nian H, Bisson WH, Dashwood WM, Pinto JT, Dashwood RH.

Carcinogenesis. 2009 Aug;30(8):1416-23. doi: 10.1093/carcin/bgp147. Epub 2009 Jun 15.

14.

The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.

Park KC, Heo JH, Jeon JY, Choi HJ, Jo AR, Kim SW, Kwon HJ, Hong SJ, Han KS.

BMC Cancer. 2015 Jan 23;15:19. doi: 10.1186/s12885-014-1003-1.

15.

Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.

Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, Chakravarty P, Paolini C, De Francesco R, Gallinari P, Steinkühler C, Di Marco S.

Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15064-9. Epub 2004 Oct 11.

16.

Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment.

Lehmann M, Hoffmann MJ, Koch A, Ulrich SM, Schulz WA, Niegisch G.

J Exp Clin Cancer Res. 2014 Jul 10;33:59. doi: 10.1186/s13046-014-0059-8.

18.

Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.

Siddiquey MN, Nakagawa H, Iwata S, Kanazawa T, Suzuki M, Imadome K, Fujiwara S, Goshima F, Murata T, Kimura H.

Cancer Sci. 2014 Jun;105(6):713-22. doi: 10.1111/cas.12418. Epub 2014 May 13.

19.

Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.

Xue K, Gu JJ, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y.

J Cancer Res Clin Oncol. 2016 Feb;142(2):379-87. doi: 10.1007/s00432-015-2026-y. Epub 2015 Aug 28.

PMID:
26314218
20.

Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.

Krennhrubec K, Marshall BL, Hedglin M, Verdin E, Ulrich SM.

Bioorg Med Chem Lett. 2007 May 15;17(10):2874-8. Epub 2007 Feb 25.

PMID:
17346959

Supplemental Content

Support Center